LONDON (Reuters) -Britain’s main pharmaceutical lobby group said on Wednesday foreign investment in the sector has fallen due to its approach to drug pricing, as the industry remains locked in dispute over the issue with the UK government.

Drug companies have been in long-running negotiations with British ministers over how much revenue from UK sales firms must return to the country’s National Health Service, and the latest talks broke down last month without a resolution.

The dispute continues as U.S. President Donald Trump applies pressure on Britain and the European Union to spend more on drugs from U.S. firms, with the administration still mulling plans for pharmaceutical tariffs.

In a report released on Wednesday into the outlook of the pharmaceutical sector, the Association of the

See Full Page